ROIV
Roivant Sciences Ltd.Healthcare · $25.9B market cap
Verdict
We can't put a fair value on ROIV right now. It has fewer than 5 profitable years and uneven cash flow, not enough history to project from yet.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow ROIV
Track it on your watchlist and see the full analysis. Free.
Create a free accountSuperinvestors
3 of the investors we track hold ROIV. In Q2 2026, 1 opened a position and 1 added. Who we track
Insider activity
Since Aug 28, 2026: no open-market purchases, 3 sales worth $8.0M and 2 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
Fitzgerald Meghan
director · 2026-09-08
Sold
$798K
Venker Eric
President & Immunovant CEO · 2026-08-28
Sold
$1.2M
Venker Eric
President & Immunovant CEO · 2026-08-28
Sold
$5.9M
Other filings
About Roivant Sciences Ltd.
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works